|
Virtual Meetings 2021
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal CancersFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Dirk Arnold, MD, PhD Director Asklepios Tumorzentrum Hamburg Asklepios Klinik Altona Hamburg, Germany Tanios Bekaii-Saab, MD Professor, Mayo Clinic College of Medicine and Science Program Leader, Gastrointestinal Cancer Mayo Clinic Cancer Center (AZ, FL and MN) Consultant, Mayo Clinic in Arizona Phoenix, Arizona Johanna Bendell, MD Chief Development Officer Director, Drug Development Unit Nashville Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee Daniel Catenacci, MD Associate Professor, Department of Medicine Section of Hematology and Oncology Director, Interdisciplinary Gastrointestinal Oncology Program Assistant Director, Translational Research Comprehensive Cancer Center The University of Chicago Medical Center and Biological Sciences Chicago, Illinois Kristen K Ciombor, MD, MSCI Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville, Tennessee Axel Grothey, MD Director, GI Cancer Research West Cancer Center and Research Institute Medical Director OneOncology Research Network Germantown, Tennessee Wells A Messersmith, MD Professor and Head, Division of Medical Oncology Associate Director for Translational Research University of Colorado Cancer Center Aurora, Colorado Eileen M O’Reilly, MD Winthrop Rockefeller Endowed Chair in Medical Oncology Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers Co-Director, Medical Initiatives David M Rubenstein Center for Pancreatic Cancer Research Attending Physician, Member Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York Philip Agop Philip, MD, PhD, FRCP Professor of Oncology and Pharmacology Leader, GI and Neuroendocrine Oncology Vice President of Medical Affairs Karmanos Cancer Institute Wayne State University Detroit, Michigan Alan P Venook, MD The Madden Family Distinguished Professor of Medical Oncology and Translational Research Shorenstein Associate Director, Program Development Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California Zev Wainberg, MD, MSc Associate Professor, Department of Medicine Director, Early Phase Clinical Research Support Co-Director, UCLA GI Oncology Program Jonsson Comprehensive Cancer Center Los Angeles, California SERIES MODERATOR Neil Love, MD Research To Practice Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer MODULE 2: Evidence-Based Management of Advanced Hepatocellular Carcinoma MODULE 3: Optimizing Personalized Treatment for Metastatic Colorectal Cancer
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Prof Arnold — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, Lilly, Merck Serono, Roche Laboratories Inc, Samsung Bioepis, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Servier, Sirtex Medical Ltd, Terumo Medical Corporation; Data and Safety Monitoring Board/Committee: Lilly. Dr Bekaii-Saab — Consulting Agreements (to Institution): Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Foundation Medicine, Janssen Biotech Inc, Natera Inc, Sobi, Treos Bio, Xilis; Contracted Research (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Lilly, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687. Dr Bendell — Advisory Committee (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, IGM Biosciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MabSpace Biosciences, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, NeoImmune Tech, NGM Biopharmaceuticals, Novartis, Novocure Inc, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Sumitomo Dainippon Pharma Oncology Inc, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Treadwell Therapeutics, Tyrogenex, Unum Therapeutics, Vyriad, Zymeworks; Consulting Agreements (to Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Fusion Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Piper Biotech, Prelude Therapeutics, Relay Therapeutics, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Torque Therapeutics, Translational Drug Development. Dr Catenacci — Advisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus. Dr Ciombor — Consulting Agreements: Merck, Natera Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc. Dr Grothey — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Merck, Natera Inc, OBI Pharma Inc, Pfizer Inc, Seagen Inc; Consulting Agreements and Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Merck, Natera Inc, OBI Pharma Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Mirati Therapeutics, Regeneron Pharmaceuticals Inc. Dr Messersmith — Contracted Research: ALX Oncology, BeiGene Ltd, Experimental Drug Development Centre (Singapore), Immunomedics Inc, Pfizer Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics, Zymeworks. Dr O’Reilly — Consulting Agreements: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, CytomX Therapeutics, Debiopharm Group, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Gilead Sciences Inc, HelioHealth, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MiNA Therapeutics, Polaris Group, QED Therapeutics, RedHill Biopharma Ltd, Silenseed Ltd, SillaJen, Sobi, TheraBionic, twoXAR, Vector Pharma, Yiviva; Contracted Research: Acta Biológica, Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Bristol-Myers Squibb Company, CASI Pharmaceuticals Inc, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Halozyme Inc, Incyte Corporation, MabVax Therapeutics, Puma Biotechnology Inc, QED Therapeutics, SillaJen, Yiviva. Dr Philip — Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, QED Therapeutics, Rafael Pharmaceuticals Inc; Consulting Agreements: Blueprint Medicines, Erytech, SynCore Biotechnology, TriSalus Life Sciences; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Incyte Corporation, Natera, Inc, Novocure Inc, QED Therapeutics, Rafael Pharmaceuticals Inc, Taiho Oncology Inc, Tyme Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech; Speaker’s Bureau: Bayer HealthCare Pharmaceuticals, Incyte Corporation. Dr Venook — Advisory Committee: Amgen Inc, Genentech, a member of the Roche Group, GlaxoSmithKline; Contracted Research: Amgen Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, QED Therapeutics. Dr Wainberg — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by an educational grant from Lilly. |